Intuitive Surgical stock holds near $398 as Q2 2026 growth stays strong
Published on 08/20/2026 at 16:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical (ISIN US46120E6023) stock is trading close to $397.72 as of the Nasdaq close on August 19, 2026, with the shares up 1.67% for that session according to an updated market-data overview Intuitive Surgical quote and overview. The company recently reported fiscal Q2 2026 results showing revenue growth of 19% to $2.89 billion and adjusted earnings per share of $2.80, with earnings exceeding consensus expectations by $0.30 Coverage of Intuitive Surgical Q2 2026 results. For investors, the combination of double-digit growth and a stock price that is still well below some fair-value estimates is shaping the current debate on valuation Intuitive Surgical valuation narrative overview.
Q2 2026 results show 19 percent revenue growth
In its fiscal Q2 2026 report, Intuitive Surgical delivered revenue of $2.89 billion, representing growth of 19% year over year for the quarter Coverage of Intuitive Surgical Q2 2026 results. Adjusted earnings per share reached $2.80 in the same period, which exceeded the prior consensus estimate by $0.30 Coverage of Intuitive Surgical Q2 2026 results. The combination of revenue growth close to 20% and an upside surprise on EPS reinforces the narrative that the company continues to scale its installed base and procedure volumes efficiently.
Commentary on the results highlights that Intuitive Surgical maintained its full-year procedure growth outlook following Q2 2026, even as it refrained from raising guidance in light of more demanding comparisons in the second half of the year Intuitive Surgical Asia-Pacific expansion commentary. Maintaining guidance while posting a 19% revenue increase and an EPS beat indicates that management is balancing confidence in the current trajectory with caution toward macro and comparison risks.
Penang manufacturing hub and Asia-Pacific expansion
Beyond near-term earnings, Intuitive Surgical is deepening its manufacturing footprint in Asia with a new facility in Penang, Malaysia, that is planned to represent investment of nearly $500 million over the first five years of operations Coverage of Intuitive investment plans in Penang. Company commentary indicates that this site will establish a major manufacturing presence in the region, supporting global demand for robotic-assisted surgery systems and potentially shortening lead times for customers across Asia-Pacific Intuitive Surgical Asia-Pacific expansion commentary. The expansion is also framed as a way to diversify the supply chain and support future growth without concentrating production in a single geography.
The decision to commit up to $500 million to Penang over five years represents a capital allocation choice that investors can compare with the companys current earnings power. Using the Q2 2026 revenue run-rate of $2.89 billion for one quarter, annualized revenue would stand near $11.6 billion if similar growth persisted, which underscores that the planned Penang investment equates to less than half of a single years current revenue base Coverage of Intuitive Surgical Q2 2026 results Coverage of Intuitive investment plans in Penang. For long-term holders, this scale suggests that the Penang facility is significant but manageable against the backdrop of current operations.
Valuation narratives and share-price context
On the market side, an updated overview of Intuitive Surgical notes that the stock closed at $397.72 on August 19, 2026, with a gain of 1.67% for that session and a 30 day share price return of 12.61% Intuitive Surgical quote and overview Intuitive Surgical valuation narrative overview. At the same time, the same overview highlights that the shares are down 29.23% on a year-to-date basis, indicating a sharp pullback earlier in 2026 despite the strong recent month-long rebound Intuitive Surgical valuation narrative overview. This divergence between short-term and year-to-date performance is central to current positioning discussions, with some investors viewing the recent recovery as a partial reversal of prior weakness.
One valuation narrative compiled in this analysis set places a fair-value estimate for Intuitive Surgical at $630.48 per share, well above the last close of $397.72 Intuitive Surgical valuation narrative overview. That gap equates to a difference of $232.76 per share between this implied fair value and the current price level, indicating potential upside from the perspective of that model if assumptions hold. For investors, the key question is whether the 19% revenue growth in Q2 2026 and ongoing expansion investments, such as the Penang facility, can sustain the type of growth that underpins such valuation estimates.
da Vinci 5 platform as a strategic product
Recent commentary also emphasizes the software-centric da Vinci 5 platform as a strategic element in Intuitive Surgicals product roadmap, with the platform aligning with a broader trend toward integrating advanced software and data capabilities into surgical robotics Intuitive Surgical valuation narrative overview. The da Vinci 5 platform is framed as part of a multi-year effort to enhance precision, workflow integration, and analytics for surgeons and hospitals, which may help support higher utilization rates and procedural volume. Although detailed unit or revenue figures for da Vinci 5 are not yet highlighted in the current reporting snapshot, the platform is frequently mentioned alongside the companys growth narrative and investment in manufacturing capacity, including the Penang facility.
By pairing the da Vinci 5 platform with expanded manufacturing in Asia-Pacific, Intuitive Surgical positions itself to serve more hospitals in the region while potentially lowering logistical and production costs. This combination of technological and geographic expansion could help maintain procedure growth within the range implied by current guidance, even as management acknowledges tougher comparisons in the second half of the year Intuitive Surgical Asia-Pacific expansion commentary. For long-term investors, the evolution of the da Vinci 5 platform alongside new manufacturing capacity will be a key driver of both revenue growth and margin trends.
Stock level relative to recent performance
At $397.72 per share as of the close on August 19, 2026, Intuitive Surgical stock sits well below at least one fair-value estimate of $630.48, while still reflecting strong recent gains after a period of weakness Intuitive Surgical quote and overview Intuitive Surgical valuation narrative overview. The 12.61% 30 day share price return compared with a year-to-date decline of 29.23% underscores that much of the stocks 2026 story has involved volatility and re-rating, even as the business delivered a 19% revenue increase and $2.80 in adjusted EPS in Q2 2026 Coverage of Intuitive Surgical Q2 2026 results. For investors weighing entry or adding exposure, this combination of recent recovery, earlier drawdown, and solid fundamentals is central to the current risk-reward discussion.
da Vinci surgical systems in everyday use
In everyday clinical practice, Intuitive Surgicals da Vinci surgical systems are used for a wide range of minimally invasive procedures, including gynecologic, urologic, and general surgery applications. The systems are designed to offer surgeons enhanced visualization, precision, and control through robotic-assisted instruments and high-definition imaging. Hospitals typically invest in da Vinci platforms with the expectation that the technology will support shorter patient recovery times and potentially lower complication rates, which can be important for both clinical outcomes and hospital economics.
As Intuitive Surgical develops software-centric upgrades like the da Vinci 5 platform, the company is focusing not only on the robotic hardware but also on integration with hospital information systems, analytics, and workflow optimization. These enhancements can help surgeons plan procedures more effectively and allow hospital administrators to track utilization and outcomes more closely. Over time, the ability to demonstrate measurable improvements in clinical and economic metrics will likely influence how rapidly hospitals adopt newer generations of the platform.
Stock snapshot and investor angle
Intuitive Surgical stock closed at $397.72 on the Nasdaq on August 19, 2026, with a single-session gain of 1.67% and a 30 day advance of 12.61%, against a year-to-date decline of 29.23% according to recent market-data analysis Intuitive Surgical quote and overview Intuitive Surgical valuation narrative overview. The shares trade on the Nasdaq, and the company is a member of the S&P 500 index, giving it visibility in many diversified portfolios. Against this backdrop, the fiscal Q2 2026 revenue of $2.89 billion, adjusted EPS of $2.80, and ongoing investment in a $500 million Penang manufacturing hub create a blend of growth and capital deployment that investors will continue to monitor in the coming quarters Coverage of Intuitive Surgical Q2 2026 results Coverage of Intuitive investment plans in Penang.
Read more
More on Intuitive Surgical stock and the companys investor materials can be found in its official investor-relations resources.
da Vinci 5 platform highlights
The da Vinci 5 platform is highlighted as a software-centric evolution of Intuitive Surgicals core robotic-assisted surgery offering, with a focus on enhanced imaging, improved ergonomics for surgeons, and advanced data capabilities Intuitive Surgical valuation narrative overview. For hospitals, the platform is intended to allow more precise control of instruments and better integration with existing operating-room infrastructure, enabling smoother workflows. As adoption progresses, metrics such as procedure volumes per installed system and utilization rates across specialties will help show how effectively the platform is being used.
Intuitive Surgical stock and recent price context
As of the close on August 19, 2026, at 4:00 p.m. ET, Intuitive Surgical stock traded at $397.72 on the Nasdaq in USD, reflecting a 1.67% gain for the session and a 12.61% 30 day return, offset by a 29.23% decline on a year-to-date basis Intuitive Surgical quote and overview Intuitive Surgical valuation narrative overview. Those figures frame the stock as one that has recently rebounded yet remains below some fair-value models, while Q2 2026 fundamentals that include $2.89 billion of revenue and adjusted EPS of $2.80 provide the earnings backdrop for that price Coverage of Intuitive Surgical Q2 2026 results.
Fact box
Company: Intuitive Surgical Inc.
ISIN: US46120E6023
Ticker: ISRG
Exchange: Nasdaq
Price (as of August 19, 2026, 4:00 p.m. ET): $397.72 USD
Sector / Industry: Health Care / Health Care Equipment
Index membership: S&P 500
